Lineage Cell Therapeutics (LCTX) Divestments (2018)

Lineage Cell Therapeutics (LCTX) posted quarterly Divestments of $3.2 million for Q1 2018.

Lineage Cell Therapeutics (LCTX) Divestments (2018) Analysis & Trends

Lineage Cell Therapeutics' Divestments history runs 1 years deep, the most recent figure standing at $3.2 million for Q1 2018.

In Q1 2018, Divestments changed N/A year-over-year to $3.2 million; the TTM figure through Dec 2018 stood at $3.2 million (changed N/A YoY), while the FY2018 annual figure was $3.2 million, changed N/A from the prior year.
Divestments for Q1 2018 stood at $3.2 million.
The five-year high for Divestments was $3.2 million in Q1 2018, with the low at $3.2 million in Q1 2018.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	9.82 Mn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-13.21 Mn
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Lineage Cell Therapeutics	270.61 Mn	212.77 Mn	1.07 Mn	-

Historic Data

Download Data

Date	Value
Mar 31, 2018	3.22 Mn